Related Experiment Video

Updated: Jul 4, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Pediatric soft tissue sarcomas

David M Loeb1, Katherine Thornton, Ori Shokek

  • 1Oncology and Pediatrics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Bunting-Blaustein Cancer Research Building, Baltimore, MD 21231, USA. loebda@jhmi.edu

The Surgical Clinics of North America
|June 3, 2008
PubMed

Insights

Pediatric soft tissue sarcomas, including rhabdomyosarcoma (RMS) and non-RMS soft tissue sarcomas (NRSTS), are rare cancers. This review covers their causes, biology, and treatment options.

Area of Science:

  • Pediatric Oncology
  • Cancer Biology
  • Surgical Oncology

Background:

  • Soft tissue sarcomas (STS) are rare in children, with approximately 850-900 annual diagnoses in the US.
  • Rhabdomyosarcoma (RMS) predominantly affects younger children (≤14 years), while non-RMS STS (NRSTS) are more common in adolescents and young adults.
  • Infants with NRSTS present unique histological features.

Purpose of the Study:

  • To provide a comprehensive overview of pediatric soft tissue sarcomas.
  • To discuss the etiology, biology, and current treatment modalities for these rare childhood cancers.

Main Methods:

  • This is a review article.
  • Information was gathered from existing literature on pediatric soft tissue sarcomas.

Main Results:

  • Surgery is a primary treatment for pediatric STS.
  • Radiation therapy is also a significant component of treatment.
  • Adjuvant chemotherapy is standard for RMS, while chemotherapy for NRSTS is reserved for high-grade or unresectable cases.

Conclusions:

  • Pediatric soft tissue sarcomas require a multidisciplinary approach involving surgery, radiation, and chemotherapy.
  • Understanding the distinct biology of RMS and NRSTS is crucial for effective treatment stratification.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...